Q-omics provides the consensus-scored AR profile across patient tissues and cancer cell-line models. AR expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AR is differentially expressed in 17, with the highest sampling consensus in THCA. Additionally, AR RNA expression shows 19,267 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, THCA, and BRCA as cancer lineages where AR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AR survival associations across molecular data types. AR RNA expression shows survival associations in the most cancer types (29), followed by mutation status (10) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AR RNA expression–survival associations across cancer types. High AR expression shows unfavorable associations in LGG, but favorable associations in KIRC, KIRP, HNSC, ACC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AR RNA expression.
This table summarizes AR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for AR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AR shows lower tumor expression in THCA, UCEC, LUSC, HNSC and LUAD and higher tumor expression in KIRC. The THCA box plot shows higher AR RNA expression in normal versus tumor tissue (log2 FC = −2.045, t-test p < 0.001).
This table shows molecular features associated with AR in patient tissues and cancer cell lines. In patient samples, AR shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, AR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
